Trimethylamine N-oxide and risk stratification after acute myocardial infarction

Clinical Chemistry

Volumn 63, Issue 1, 2017, Pages 420-428

  Suzuki, Toru ^a,b   Heaney, Liam M ^a   Jones, Donald J L ^a,c   Ng, Leong L ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; COPEPTIN; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIMETHYLAMINE OXIDE; TROPONIN I; UREA; METHYLAMINE; TRIMETHYLOXAMINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); CREATINE KINASE BLOOD LEVEL; DECISION TREE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; Q WAVE; RECURRENT DISEASE; ST SEGMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UREA BLOOD LEVEL; ACUTE DISEASE; BLOOD; HEART INFARCTION; MIDDLE AGED; RISK ASSESSMENT; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOMARKERS; FEMALE; HUMANS; MALE; METHYLAMINES; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK ASSESSMENT;

EID: 85008440685     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.264853     Document Type: Article

References (29)

1. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of6-monthpostdischargedeathinaninternationalregistry. JAMA 2004;291:2727-33.
2. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
3. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000;101:2557-67.
4. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007;115:2103-10.
5. Ng LL, Sandhu JK, Narayan H, Quinn PA, Squire IB, Davies JE, et al. Proenkephalin and prognosis after acute myocardial infarction. J Am Coll Cardiol 2014;63:280-9.
6. Dhillon OS, Khan SQ, Narayan HK, Ng KH, Struck J, Quinn PA, et al. Prognostic value of mid-regional proadrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. J Am Coll Cardiol 2010;56:125-33.
7. Ng LL, Sandhu JK, Narayan H, Quinn PA, Squire IB, Davies JE, et al. Pro-substance P for evaluation of risk in acute myocardial infarction. J AmColl Cardiol 2014;64:1698-707.
8. Amaki T, Suzuki T, Nakamura F, Hayashi D, Imai Y, Morita H, et al. Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease. Heart 2004;90:1211-3.
9. Suzuki T, Kohno H, Hasegawa A, Toshima S, Amaki T, Kurabayashi M, et al. Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease. Clin Biochem 2002;35:347-53.
10. Fujimoto H, Suzuki T, Aizawa K, Sawaki D, Ishida J, Ando J, et al. Processed B-type natriuretic peptide is a biomarker of postinterventional restenosis in ischemic heart disease. Clin Chem 2013;59:1330-7.
11. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011;472:57-63.
12. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013;368:1575-84.
13. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19:576-85.
14. Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 2013;17:49-60.
15. Miao J, Ling AV, Manthena PV, Gearing ME, Graham MJ, Crooke RM, et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun 2015;6:6498.
16. Seldin MM, Meng Y, Qi H, Zhu W, Wang Z, Hazen SL, et al. Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB. J Am Heart Assoc 2016;5:e002767.
17. Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 2014;64:1908-14.
18. Suzuki T, Heaney LM, Bhandari SS, Jones DJL, Ng LL. Trimethylamine N-oxide and prognosis in acute heart failure. Heart 2016;102:841-8.
19. Rhee EP, Clish CB, Ghorbani A, Larson MG, Elmariah S, McCabe E, et al. A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol 2013;24:1330-8.
20. Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015;116:448-55.
21. Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 2016;165:111-24.
22. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Jaffe AS, Apple FS, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
23. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;114:1572-80.
24. Heaney LM, Jones DJ, Mbasu RJ, Ng LL, Suzuki T. High mass accuracy assay for trimethylamine N-oxide using stable-isotope dilution with liquid chromatography coupled to orthogonal acceleration time of flight mass spectrometry with multiple reaction monitoring. Anal Bioanal Chem 2016;408:797-804.
25. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-8.
26. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
27. Global Registry of Acute Coronary Events. GRACE risk table. https://www.outcomes-umassmed.org/GRACE/grace risk table.aspx (Accessed February 2016).
28. Senthong V, Li XS, Hudec T, Coughlin J, Wu Y, Levison B, et al. Plasma trimethylamine N-oxide, a gut microbegenerated phosphatidylcholine metabolite, is associated with atherosclerotic burden. J Am Coll Cardiol 2016;67:2620-8.
29. Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 2015;163:1585-95.